MEI Pharma (MEIP) stock price, revenue, and financials

MEI Pharma market cap is $391.6 m, and annual revenue was $28.91 m in FY 2020

$391.6 M

MEIP Mkt cap, 11-May-2021

$2.4 M

MEI Pharma Revenue Q3, 2021
MEI Pharma Gross profit (Q3, 2021)2 M
MEI Pharma Gross profit margin (Q3, 2021), %83.3%
MEI Pharma Net income (Q3, 2021)-31.3 M
MEI Pharma EBIT (Q3, 2021)-22.1 M
MEI Pharma Cash, 31-Mar-20219.7 M
MEI Pharma EV390.4 M

MEI Pharma Income Statement

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

23.2m1.6m4.9m28.9m

Cost of goods sold

5.0m3.4m4.3m2.7m

Gross profit

18.2m(1.8m)652.0k26.2m

Gross profit Margin, %

78%(109%)13%91%

R&D expense

4.9m6.1m7.2m17.0m32.3m34.1m

General and administrative expense

3.5m5.1m8.6m9.8m14.6m16.7m

Operating expense total

8.4m11.2m15.9m26.8m46.9m50.8m

EBIT

(8.4m)(11.2m)(27.2m)(32.8m)(21.0m)2.4m(28.6m)(46.2m)(24.5m)

EBIT margin, %

10%(1762%)(941%)(85%)

Interest expense

871.0k

Interest income

39.0k37.0k81.0k78.0k143.0k287.0k591.0k1.8m1.4m

Pre tax profit

(7.5m)(11.2m)(27.1m)(32.7m)(20.9m)2.7m(40.1m)(16.8m)(46.0m)

Income tax expense

1.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k

Net Income

(7.5m)(11.2m)(27.1m)(32.7m)(20.9m)2.7m(40.1m)(16.8m)(46.0m)

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q2, 2021Q3, 2021

Revenue

1.1m17.2m4.5m283.0k358.0k433.0k488.0k2.0m1.2m1.2m1.0m1.2m9.2m2.4m

Cost of goods sold

1.1m1.8m1.1m618.0k728.0k930.0k989.0k1.0m1.2m688.0k641.0k860.0k494.0k405.0k

Gross profit

2.0k15.4m3.4m(335.0k)(370.0k)(497.0k)(501.0k)1.0m86.0k469.0k367.0k384.0k8.7m2.0m

Gross profit Margin, %

0%90%75%(118%)(103%)(115%)(103%)51%7%41%36%31%95%83%

R&D expense

1.0m1.1m1.5m1.6m1.3m1.5m6.1m3.4m3.1m6.1m9.1m9.1m9.0m8.3m9.0m22.2m17.9m

General and administrative expense

889.0k896.0k811.0k914.0k1.4m1.2m2.5m2.4m2.5m3.4m3.8m3.6m4.1m4.2m3.9m5.7m6.2m

Operating expense total

1.9m2.0m2.3m2.5m2.8m2.8m4.3m3.6m4.0m8.6m5.8m5.6m9.5m12.9m12.7m13.1m12.5m12.8m27.9m24.1m

EBIT

(1.9m)(2.0m)(2.3m)(2.5m)(2.8m)(2.8m)(4.9m)(6.3m)(7.4m)(9.0m)(9.1m)(9.0m)(4.6m)(5.1m)(5.4m)(4.3m)11.8m(670.0k)(8.9m)(6.2m)(6.1m)(10.0m)(11.8m)(12.6m)(12.6m)(12.1m)(12.4m)(19.2m)(22.1m)

EBIT margin, %

(395%)69%(15%)(3140%)(1724%)(1398%)(2056%)(579%)(1010%)(1091%)(1201%)(1000%)(209%)(913%)

Interest income

3.0k2.0k32.0k3.0k2.0k15.0k18.0k25.0k19.0k12.0k10.0k30.0k27.0k26.0k39.0k55.0k69.0k68.0k100.0k93.0k106.0k454.0k436.0k462.0k374.0k318.0k382.0k164.0k58.0k

Income tax expense

1.0k1.0k1.0k1.0k1.0k1.0k1.0k1.0k

Net Income

(1.6m)(1.5m)(2.3m)(2.5m)(2.8m)(2.8m)(4.9m)(6.3m)(7.4m)(9.0m)(9.1m)(8.9m)(4.6m)(5.1m)(5.4m)(4.3m)11.9m(602.0k)(8.8m)(6.1m)(5.9m)(14.5m)12.0m(17.4m)(3.0m)(20.2m)(4.3m)(11.5m)(31.3m)

MEI Pharma Balance Sheet

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

6.2m35.6m13.8m18.7m10.8m8.5m13.3m9.6m12.3m

Prepaid Expenses

146.0k456.0k497.0k502.0k1.8m1.6m2.4m5.6m

Inventories

831.0k

Current Assets

6.3m36.0m49.3m64.3m46.7m55.3m104.3m82.2m208.6m

PP&E

25.0k48.0k83.0k68.0k49.0k50.0k32.0k204.0k1.1m

Total Assets

6.4m36.5m49.8m64.8m47.2m55.7m104.7m82.7m209.7m

Accounts Payable

594.0k537.0k1.7m863.0k1.1m585.0k3.6m4.8m2.4m

Current Liabilities

1.8m1.7m4.6m5.0m5.5m4.9m7.9m14.3m23.3m

Total Liabilities

1.8m54.2m34.7m131.5m

Common Stock

20.5m17.1m73.5m111.5m

Preferred Stock

Additional Paid-in Capital

89.7m131.2m168.6m215.9m218.7m225.2m264.9m279.1m355.5m

Retained Earnings

(85.1m)(96.3m)(123.4m)(156.1m)(177.0m)(174.3m)(214.4m)(231.2m)(277.2m)

Total Equity

4.6m34.9m45.2m59.8m41.7m50.8m50.5m47.9m78.2m

Financial Leverage

1.4 x1 x1.1 x1.1 x1.1 x1.1 x2.1 x1.7 x2.7 x

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q2, 2021Q3, 2021

Cash

4.8m5.0m2.7m3.7m26.9m24.2m31.5m39.8m19.7m17.0m23.7m20.5m17.9m13.7m14.3m13.8m15.1m11.6m7.0m7.3m6.2m6.1m8.7m7.4m6.0m8.6m7.4m9.9m9.7m

Prepaid Expenses

108.0k200.0k543.0k123.0k197.0k260.0k602.0k893.0k861.0k353.0k533.0k592.0k596.0k787.0k1.1m1.7m2.7m2.8m641.0k772.0k854.0k3.7m2.4m3.2m2.1m2.6m2.6m13.9m11.9m

Current Assets

4.9m5.2m3.3m3.8m27.1m24.4m32.1m60.7m55.5m42.4m79.2m71.1m58.6m54.6m50.5m60.6m57.8m59.5m47.7m43.2m37.1m94.4m95.8m85.4m68.1m106.4m95.4m194.0m176.6m

PP&E

35.0k31.0k28.0k23.0k22.0k41.0k50.0k46.0k61.0k75.0k79.0k77.0k62.0k56.0k53.0k46.0k40.0k35.0k45.0k40.0k36.0k28.0k193.0k213.0k619.0k416.0k986.0k1.6m1.6m

Total Assets

4.9m5.2m3.3m4.4m27.6m24.9m32.6m61.2m56.0m42.9m79.7m71.6m59.1m55.0m50.9m61.0m58.2m59.9m48.0m43.6m37.4m94.8m96.3m85.9m68.9m107.1m96.6m203.9m186.1m

Accounts Payable

331.0k381.0k441.0k533.0k448.0k528.0k557.0k809.0k700.0k1.1m2.2m2.7m253.0k448.0k466.0k749.0k382.0k242.0k751.0k1.1m1.3m1.6m2.2m2.0m3.1m3.0m2.5m5.6m5.6m

Short-term debt

873.0k900.0k

Current Liabilities

1.6m1.3m1.5m1.6m1.8m1.8m1.5m2.4m3.5m5.3m6.9m6.6m3.1m3.4m4.0m17.2m3.3m5.0m4.5m5.2m4.5m4.8m10.9m11.9m10.1m9.9m10.3m37.0m33.4m

Long-term debt

7.8m7.6m

Total Debt

8.7m8.5m

Total Liabilities

18.7m55.0m42.8m48.0m21.6m29.8m22.1m130.4m141.2m

Common Stock

11.8m14.7m14.7m21.7m15.0m15.0m17.1m21.5m21.6m73.7k106.0k106.0k112.5m112.6m

Preferred Stock

Additional Paid-in Capital

82.6m84.7m84.8m90.3m116.1m116.2m132.3m166.2m167.4m170.0m214.4m215.4m216.7m217.5m218.1m223.6m224.3m224.9m226.7m227.6m228.1m268.7m270.4m272.2m281.5m331.7m333.3m364.3m367.1m

Retained Earnings

(79.2m)(80.7m)(83.0m)(87.6m)(90.3m)(93.1m)(101.2m)(107.5m)(114.9m)(132.4m)(141.5m)(150.5m)(160.8m)(165.9m)(171.2m)(181.3m)(169.4m)(170.0m)(183.1m)(189.2m)(195.1m)(228.9m)(216.9m)(234.3m)(234.2m)(254.4m)(258.8m)(290.8m)(322.1m)

Total Equity

3.4m3.9m1.8m2.7m25.8m23.2m31.2m58.7m52.5m37.6m72.9m65.0m55.9m51.6m46.9m42.3m54.9m54.9m43.6m38.4m32.9m39.8m53.5m37.9m47.3m77.3m74.5m73.5m45.0m

Financial Leverage

1.5 x1.3 x1.8 x1.6 x1.1 x1.1 x1 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.4 x1.1 x1.1 x1.1 x1.1 x1.1 x2.4 x1.8 x2.3 x1.5 x1.4 x1.3 x2.8 x4.1 x

MEI Pharma Cash Flow

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q2, 2021Q3, 2021

Net Income

(1.6m)(3.2m)(5.4m)(2.5m)(5.2m)(8.0m)(4.9m)(11.2m)(18.6m)(9.0m)(18.1m)(27.0m)(4.6m)(9.7m)(15.1m)(4.3m)7.6m7.0m(8.8m)(14.9m)(20.8m)(14.5m)(2.5m)(19.9m)(3.0m)(23.2m)(27.5m)(13.5m)(44.9m)

Depreciation and Amortization

3.0k7.0k10.0k8.0k19.0k33.0k13.0k24.0k34.0k16.0k31.0k48.0k15.0k30.0k45.0k14.0k29.0k42.0k14.0k27.0k40.0k13.0k28.0k52.0k31.0k60.0k90.0k143.0k215.0k

Accounts Receivable

(131.0k)(45.0k)(51.0k)(326.0k)(96.0k)(74.0k)2.2m

Accounts Payable

3.0k53.0k113.0k(61.0k)(146.0k)(66.0k)20.0k272.0k163.0k(597.0k)444.0k1.0m(610.0k)(415.0k)(397.0k)(330.0k)(697.0k)(837.0k)166.0k504.0k674.0k(2.1m)(1.5m)(1.7m)(1.7m)(1.7m)(2.3m)3.1m3.1m

Cash From Operating Activities

(1.7m)(3.5m)(5.8m)(2.5m)(4.6m)(7.3m)(4.1m)(8.5m)(13.6m)(6.7m)(13.2m)(21.3m)(5.8m)(10.0m)(14.4m)8.8m5.0m6.6m(6.6m)(11.3m)(17.6m)(12.8m)(10.0m)(21.4m)(14.1m)(24.6m)(34.9m)(5.1m)(20.7m)

Purchases of PP&E

(2.0k)(4.0k)(28.0k)(6.0k)(5.0k)(21.0k)(10.0k)(16.0k)(3.0k)(2.0k)(2.0k)(2.0k)(172.0k)(207.0k)(5.0k)(785.0k)(700.0k)(700.0k)

Cash From Investing Activities

(2.0k)(4.0k)(28.0k)(6.0k)(20.0m)(35.0m)10.0m(20.0m)(15.1m)4.9m4.9m9.9m(10.0m)(5.0m)(10.0m)5.0m10.0m15.1m4.8m4.6m14.4m5.0m(30.3m)(21.2m)(668.0k)14.7m

Cash From Financing Activities

2.7m4.6m4.6m25.3m25.3m32.7m32.7m43.1m43.1m4.2m4.2m4.2m20.0k189.0k189.0k837.0k861.0k1.1m5.5m54.0m53.9m3.3m3.4m

Net Change in Cash

942.0k1.1m(1.1m)(2.5m)20.7m18.0m(4.1m)4.2m(15.9m)3.3m9.9m6.7m(846.0k)(5.0m)(4.4m)3.0m4.2m807.0k(1.5m)(1.1m)(2.3m)(7.2m)(4.6m)(5.9m)(3.6m)(952.0k)(2.2m)(2.5m)(2.6m)

Income Taxes Paid

(1.0k)(1.0k)(1.0k)(8.0k)(8.0k)

MEI Pharma Ratios

USDQ1, 2012

Financial Leverage

1.5 x